{'52WeekChange': -0.5666667,
 'SandP52WeekChange': 0.0644362,
 'address1': '1900 Powell Street',
 'address2': 'Suite 1000',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.61,
 'askSize': 800,
 'averageDailyVolume10Day': 238962,
 'averageVolume': 440607,
 'averageVolume10days': 238962,
 'beta': 1.803921,
 'beta3Year': None,
 'bid': 2.6,
 'bidSize': 1200,
 'bookValue': -0.563,
 'category': None,
 'circulatingSupply': None,
 'city': 'EmeryVille',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.63,
 'dayLow': 2.49,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.255,
 'enterpriseToRevenue': 1.654,
 'enterpriseValue': 95049336,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '510 428 0519',
 'fiftyDayAverage': 2.709143,
 'fiftyTwoWeekHigh': 7.78,
 'fiftyTwoWeekLow': 1.9,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 20331632,
 'forwardEps': -1.3,
 'forwardPE': -2,
 'fromCurrency': None,
 'fullTimeEmployees': 136,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.028110001,
 'heldPercentInstitutions': 0.79065,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/adamaspharma.com',
 'longBusinessSummary': 'Adamas Pharmaceuticals, Inc. focuses on the '
                        'discovery, development, and commercialization of '
                        'medicines for patients suffering from chronic '
                        'neurologic disorders in the United States. The '
                        'company offers GOCOVRI, an extended release capsule '
                        'for the treatment of dyskinesia in patients with '
                        "Parkinson's disease receiving levodopa-based therapy, "
                        'with or without concomitant dopaminergic medications. '
                        'It is also developing ADS-5102 that is in Phase III '
                        'clinical study to treat walking impairment in '
                        'patients with multiple sclerosis and other '
                        'indications; and ADS-4101, which has completed two '
                        'Phase I studies for treating partial onset seizures '
                        'in patients with epilepsy. In addition, the company '
                        'offers Namzaric (memantine hydrochloride extended '
                        'release and donepezil hydrochloride) capsules for the '
                        'treatment of moderate to severe dementia of an '
                        "Alzheimer's type. The company was formerly known as "
                        'NeuroMolecular Pharmaceuticals, Inc. and changed its '
                        'name to Adamas Pharmaceuticals, Inc. in July 2007. '
                        'Adamas Pharmaceuticals, Inc. was founded in 2000 and '
                        'is headquartered in Emeryville, California.',
 'longName': 'Adamas Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 73211320,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_49682935',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -92176000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.6,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.03,
 'phone': '510 450 3500',
 'previousClose': 2.61,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 1.274282,
 'profitMargins': -1.60437,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.63,
 'regularMarketDayLow': 2.49,
 'regularMarketOpen': 2.6,
 'regularMarketPreviousClose': 2.61,
 'regularMarketPrice': 2.6,
 'regularMarketVolume': 309152,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 28158200,
 'sharesPercentSharesOut': 0.033099998,
 'sharesShort': 931410,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1043883,
 'shortName': 'Adamas Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0398,
 'shortRatio': 1.34,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ADMS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.313,
 'twoHundredDayAverage': 3.5635252,
 'volume': 309152,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.adamaspharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94608'}